Advances in drug therapy for systemic lupus erythematosus (Q33757883)

29 July 2017

8 references

12 March 2019

13 March 2019

17 June 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

29 October 2020

Advances in drug therapy for systemic lupus erythematosus (English)

1 reference

systemic lupus erythematosus

29 July 2017

8 references

12 March 2019

13 March 2019

17 June 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

29 October 2020

1 reference

27 September 2019

1 reference

27 November 2019

1 reference

13 December 2019

1 reference

29 October 2020

Daniel J Wallace

1

1 reference

PubMed ID

21114845

29 July 2017

language of work or name

English

0 references

publication date

29 November 2010

9 references

29 July 2017

12 March 2019

13 March 2019

17 June 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

29 October 2020

9 references

29 July 2017

12 March 2019

13 March 2019

17 June 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

29 October 2020

8

1 reference

29 July 2017

77

1 reference

Creative Commons Attribution

29 July 2017

8 references

12 March 2019

13 March 2019

17 June 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

29 October 2020

0 references

on focus list of Wikimedia project

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1741-7015-8-77

0 references

cites work

Topical calcineurin inhibitors in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3009611

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3009611

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3009611

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3009611

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3009611

Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3009611

21 June 2018

Eculizumab (Alexion).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3009611

NIH conference. Systemic lupus erythematosus: evolving concepts

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3009611

Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1741-7015-8-77

Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1741-7015-8-77

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3009611

Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients

30 October 2018

1 reference

12 December 2020

Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial

1 reference

12 December 2020

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Revised British Isles Lupus Assessment Group 2004 index: A reliable tool for assessment of systemic lupus erythematosus activity

1 reference

12 December 2020

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

1 reference

12 December 2020

A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus

1 reference

12 December 2020

Identifiers

DOI

10.1186/1741-7015-8-77

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

PubMed ID

21114845